{"pmid":32335512,"title":"Absence of severe complications from SARS-CoV-2 infection in children with rheumatic diseases treated with biologic drugs.","text":["Absence of severe complications from SARS-CoV-2 infection in children with rheumatic diseases treated with biologic drugs.","We read with interest the Editorial by Cron and Chatam (1) suggesting a cytokine storm syndrome (CSS) occurring in response to SARS-CoV-2 infection and, consequently, a possible role for targeted approaches to blocking inflammatory cytokines.","J Rheumatol","Filocamo, Giovanni","Minoia, Francesca","Carbogno, Simone","Costi, Stefania","Romano, Micol","Cimaz, Rolando","32335512"],"abstract":["We read with interest the Editorial by Cron and Chatam (1) suggesting a cytokine storm syndrome (CSS) occurring in response to SARS-CoV-2 infection and, consequently, a possible role for targeted approaches to blocking inflammatory cytokines."],"journal":"J Rheumatol","authors":["Filocamo, Giovanni","Minoia, Francesca","Carbogno, Simone","Costi, Stefania","Romano, Micol","Cimaz, Rolando"],"date":"2020-04-27T11:00:00Z","year":2020,"_id":"32335512","week":"202018|Apr 27 - May 03","doi":"10.3899/jrheum.200483","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1665172302005796865,"score":8.518259,"similar":[{"pmid":32335514,"title":"The Question of Whether to Remain on Therapy for Chronic Rheumatic Diseases in the Setting of the Covid-19 Pandemic.","text":["The Question of Whether to Remain on Therapy for Chronic Rheumatic Diseases in the Setting of the Covid-19 Pandemic.","We appreciate our Italian colleagues' interest in our editorial denoting the rheumatologist's role in helping to diagnose and treat cytokine storm syndrome (CSS) in the setting of the Covid-19 panemic (1). It is encouraging that none of the 123 pediatric rheumatology patients (primarily juvenile idiopathic arthritis) on background biological disease modifying anti-rheumatic drug (bDMARD) therapies in Milan, Italy surveyed over a 7-week period from February 25 through April 14, 2020 (during which time Covid-19 was hyper-endemic there) had either confirmed or suspected Covid-19 (2).","J Rheumatol","Cron, Randy Q","Chatham, W Winn","32335514"],"abstract":["We appreciate our Italian colleagues' interest in our editorial denoting the rheumatologist's role in helping to diagnose and treat cytokine storm syndrome (CSS) in the setting of the Covid-19 panemic (1). It is encouraging that none of the 123 pediatric rheumatology patients (primarily juvenile idiopathic arthritis) on background biological disease modifying anti-rheumatic drug (bDMARD) therapies in Milan, Italy surveyed over a 7-week period from February 25 through April 14, 2020 (during which time Covid-19 was hyper-endemic there) had either confirmed or suspected Covid-19 (2)."],"journal":"J Rheumatol","authors":["Cron, Randy Q","Chatham, W Winn"],"date":"2020-04-27T11:00:00Z","year":2020,"_id":"32335514","week":"202018|Apr 27 - May 03","doi":"10.3899/jrheum.200492","source":"PubMed","topics":["Prevention"],"weight":1,"locations":["Italian","Milan","Italy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"_version_":1665172301974339584,"score":114.35024},{"pmid":32253068,"pmcid":"PMC7127009","title":"Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy.","text":["Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy.","The Coronavirus-associated disease, that was first identified in 2019 in China (CoViD-19), is a pandemic caused by a bat-derived beta-coronavirus, named SARS-CoV2. It shares homology with SARS and MERS-CoV, responsible for past outbreaks in China and in Middle East. SARS-CoV2 spread from China where the first infections were described in December 2019 and is responsible for the respiratory symptoms that can lead to acute respiratory distress syndrome. A cytokine storm has been shown in patients who develop fatal complications, as observed in past coronavirus infections. The management includes ventilatory support and broad-spectrum antiviral drugs, empirically utilized, as a targeted therapy and vaccines have not been developed. Based upon our limited knowledge on the pathogenesis of CoViD-19, a potential role of some anti-rheumatic drugs may be hypothesized, acting as direct antivirals or targeting host immune response. Antimalarial drugs, commonly used in rheumatology, may alter the lysosomal proteases that mediates the viral entry into the cell and have demonstrated efficacy in improving the infection. Anti-IL-1 and anti-IL-6 may interfere with the cytokine storm in severe cases and use of tocilizumab has shown good outcomes in a small cohort. Baricitinib has both antiviral and anti-inflammatory properties. Checkpoints inhibitors such as anti-CD200 and anti-PD1 could have a role in the treatment of CoViD-19. Rheumatic disease patients taking immunosuppressive drugs should be recommended to maintain the chronic therapy, prevent infection by avoiding social contacts and pausing immunosuppressants in case of infection. National and international registries are being created to collect data on rheumatic patients with CoViD-19.","J Autoimmun","Ceribelli, Angela","Motta, Francesca","De Santis, Maria","Ansari, Aftab A","Ridgway, William M","Gershwin, M Eric","Selmi, Carlo","32253068"],"abstract":["The Coronavirus-associated disease, that was first identified in 2019 in China (CoViD-19), is a pandemic caused by a bat-derived beta-coronavirus, named SARS-CoV2. It shares homology with SARS and MERS-CoV, responsible for past outbreaks in China and in Middle East. SARS-CoV2 spread from China where the first infections were described in December 2019 and is responsible for the respiratory symptoms that can lead to acute respiratory distress syndrome. A cytokine storm has been shown in patients who develop fatal complications, as observed in past coronavirus infections. The management includes ventilatory support and broad-spectrum antiviral drugs, empirically utilized, as a targeted therapy and vaccines have not been developed. Based upon our limited knowledge on the pathogenesis of CoViD-19, a potential role of some anti-rheumatic drugs may be hypothesized, acting as direct antivirals or targeting host immune response. Antimalarial drugs, commonly used in rheumatology, may alter the lysosomal proteases that mediates the viral entry into the cell and have demonstrated efficacy in improving the infection. Anti-IL-1 and anti-IL-6 may interfere with the cytokine storm in severe cases and use of tocilizumab has shown good outcomes in a small cohort. Baricitinib has both antiviral and anti-inflammatory properties. Checkpoints inhibitors such as anti-CD200 and anti-PD1 could have a role in the treatment of CoViD-19. Rheumatic disease patients taking immunosuppressive drugs should be recommended to maintain the chronic therapy, prevent infection by avoiding social contacts and pausing immunosuppressants in case of infection. National and international registries are being created to collect data on rheumatic patients with CoViD-19."],"journal":"J Autoimmun","authors":["Ceribelli, Angela","Motta, Francesca","De Santis, Maria","Ansari, Aftab A","Ridgway, William M","Gershwin, M Eric","Selmi, Carlo"],"date":"2020-04-08T11:00:00Z","year":2020,"_id":"32253068","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.jaut.2020.102442","keywords":["antimalarials","baricitinib","covid-19","rheumatic diseases","sars-cov2","tocilizumab"],"source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"locations":["China","China","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["baricitinib","tocilizumab"],"_version_":1664640769788477440,"score":112.578156},{"pmid":32290839,"pmcid":"PMC7154566","title":"Why tocilizumab could be an effective treatment for severe COVID-19?","text":["Why tocilizumab could be an effective treatment for severe COVID-19?","A severe pneumonia-associated respiratory syndrome caused by a new coronavirus was identified in December 2019 (COVID-19), spread rapidly and has become a world-wide public health challenge. About 25% of COVID-19 patients experienced severe complications including acute respiratory distress syndrome (ARDS), and even progressed into an intensive care unit (ICU) admission and died. The exploration for the mortality causes and advancing novel therapeutic development of severe COVID-19 is crucial at the moment. The biopsy samples analysis at autopsy suggested that increased alveolar exudate caused by aberrant host immune response and inflammatory cytokine storm probably impedes alveolar gas exchange and contributes to the high mortality of severe COVID-19 patients. Our research has identified that pathogenic T cells and inflammatory monocytes incite inflammatory storm with large amount of interleukin 6, therefore monoclonal antibody that targets the IL-6 pathways may potentially curb inflammatory storm. Moreover, Tocilizumab treatment that blocking IL-6 receptors showed inspiring clinical results including temperature returned to normal quickly and respiratory function improved. Therefore, we suggest that Tocilizumab is an effective treatment in severe patients of COVID-19 to calm the inflammatory storm and reduce mortality.","J Transl Med","Fu, Binqing","Xu, Xiaoling","Wei, Haiming","32290839"],"abstract":["A severe pneumonia-associated respiratory syndrome caused by a new coronavirus was identified in December 2019 (COVID-19), spread rapidly and has become a world-wide public health challenge. About 25% of COVID-19 patients experienced severe complications including acute respiratory distress syndrome (ARDS), and even progressed into an intensive care unit (ICU) admission and died. The exploration for the mortality causes and advancing novel therapeutic development of severe COVID-19 is crucial at the moment. The biopsy samples analysis at autopsy suggested that increased alveolar exudate caused by aberrant host immune response and inflammatory cytokine storm probably impedes alveolar gas exchange and contributes to the high mortality of severe COVID-19 patients. Our research has identified that pathogenic T cells and inflammatory monocytes incite inflammatory storm with large amount of interleukin 6, therefore monoclonal antibody that targets the IL-6 pathways may potentially curb inflammatory storm. Moreover, Tocilizumab treatment that blocking IL-6 receptors showed inspiring clinical results including temperature returned to normal quickly and respiratory function improved. Therefore, we suggest that Tocilizumab is an effective treatment in severe patients of COVID-19 to calm the inflammatory storm and reduce mortality."],"journal":"J Transl Med","authors":["Fu, Binqing","Xu, Xiaoling","Wei, Haiming"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32290839","week":"202016|Apr 13 - Apr 19","doi":"10.1186/s12967-020-02339-3","keywords":["acute respiratory distress syndrome (ards)","covid-19","il-6","inflammatory storm","sars-cov-2","tocilizumab"],"link_comment_in":"32290847","source":"PubMed","topics":["Treatment"],"weight":1,"e_drugs":["tocilizumab"],"_version_":1664636192640991234,"score":78.768},{"pmid":32234467,"pmcid":"PMC7118634","title":"The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality.","text":["The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality.","Since December 2019, a viral pneumonia (COVID-19) from Wuhan, China has swept the world. Although the case fatality rate is not high, the number of people infected is large, and there are still a large number of patients dying. With the collation and publication of more and more clinical data, a large number of data suggest that there are mild or severe cytokine storms in severe patients, which is also an important cause of death. Therefore, the treatment of cytokine storm has become an important part of rescuing severe patients. Interleukin-6 (IL-6) plays an important role in cytokine release syndrome (CRS). If it can block the signal transduction pathway of IL-6, it is expected to become a new method for the treatment of severe patients. Tocilizumab is a blocker of IL-6R, which can effectively block IL-6 signal transduction pathway. So, tocilizumab is likely to become an effective drug for patients with severe COVID-19.","Int J Antimicrob Agents","Zhang, Chi","Wu, Zhao","Li, Jia-Wen","Zhao, Hong","Wang, Gui-Qiang","32234467"],"abstract":["Since December 2019, a viral pneumonia (COVID-19) from Wuhan, China has swept the world. Although the case fatality rate is not high, the number of people infected is large, and there are still a large number of patients dying. With the collation and publication of more and more clinical data, a large number of data suggest that there are mild or severe cytokine storms in severe patients, which is also an important cause of death. Therefore, the treatment of cytokine storm has become an important part of rescuing severe patients. Interleukin-6 (IL-6) plays an important role in cytokine release syndrome (CRS). If it can block the signal transduction pathway of IL-6, it is expected to become a new method for the treatment of severe patients. Tocilizumab is a blocker of IL-6R, which can effectively block IL-6 signal transduction pathway. So, tocilizumab is likely to become an effective drug for patients with severe COVID-19."],"journal":"Int J Antimicrob Agents","authors":["Zhang, Chi","Wu, Zhao","Li, Jia-Wen","Zhao, Hong","Wang, Gui-Qiang"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32234467","week":"202014|Mar 30 - Apr 05","doi":"10.1016/j.ijantimicag.2020.105954","keywords":["covid-19","cytokine release syndrome","tocilizumab"],"source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["tocilizumab"],"_version_":1664638354264686592,"score":74.60134},{"pmid":32297995,"title":"High IL-6/IFN-gamma ratio could be associated with severe disease in COVID-19 patients.","text":["High IL-6/IFN-gamma ratio could be associated with severe disease in COVID-19 patients.","Cytokines are important mediators of the inflammatory response, and during infection with SARS-CoV-2 it has been suggested that there is a cytokine storm syndrome. In this study, a meta-analysis was performed to investigate whether the IL-6/IFN-gamma ratio can help predict clinical severity in patients with COVID-19. This article is protected by copyright. All rights reserved.","J Med Virol","Lagunas-Rangel, Francisco Alejandro","Chavez-Valencia, Venice","32297995"],"abstract":["Cytokines are important mediators of the inflammatory response, and during infection with SARS-CoV-2 it has been suggested that there is a cytokine storm syndrome. In this study, a meta-analysis was performed to investigate whether the IL-6/IFN-gamma ratio can help predict clinical severity in patients with COVID-19. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Lagunas-Rangel, Francisco Alejandro","Chavez-Valencia, Venice"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32297995","week":"202016|Apr 13 - Apr 19","doi":"10.1002/jmv.25900","keywords":["hyperinflammation","inflammation","interferon","interleukin","cytokine storm","lung damage"],"source":"PubMed","topics":["Diagnosis"],"weight":1,"_version_":1664641388339265538,"score":71.02668}]}